SNN Stock Recent News

The CARTIHEAL Implant will be featured at the  Arthroscopy Association of North America Annual Meeting (AANA 2025) this week

“CORI on Tour” will highlight the latest advancements in robotics-assisted surgery for hip and knee joint replacement Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces a months-long roadshow across central Europe to promote its CORI Surgical System – an advanced robotics-assisted surgical platform for total knee and hip joint replacement procedures. The tour will commence in Berlin today and make dozens of stops at surgical facilities across Germany, Austria and Switzerland until returning to Berlin on 28 October for DKOU 2025 – the largest Orthopaedics congress in Europe.

Smith & Nephew plc (NYSE:SNN ) Q1 2025 Results Conference Call April 30, 2025 3:30 AM ET Company Participants Deepak Nath - Chief Executive Officer John Rogers - Chief Financial Officer Conference Call Participants Richard Felton - Goldman Sachs Julien Dormois - Jefferies Jack Reynolds-Clark - RBC Capital Markets Lisa Clive - Bernstein Hassan Al-Wakeel - Barclays Kane Slutzkin - Deutsche Bank David Adlington - JPMorgan Veronika Dubajova - Citi Dylan van Haaften - Stifel Robert Davies - Morgan Stanley Operator Ladies and gentlemen, welcome to the Smith & Nephew Q1 Trading Report. My name is Jenny, and I will be coordinating your call today.

Smith & Nephew PLC (LSE:SN) rose as much as 7% in afternoon trading on Wednesday after the medical technology group reported stronger-than-expected revenue growth in the first quarter of 2025. The London-listed company posted underlying revenue growth of 3.1% in the three months to March, ahead market consensus of 1.9%.

Smith & Nephew PLC (LSE:SN) shares rose over 5% to top the early FTSE 100 leaderboard on Wednesday after the knee and hip replacer maintained its full-year 2025 guidance after seeing growth of 3.1% in underlying revenue for the first quarter. The performance was supported by recent product launches and continued operational improvements across its business lines, with total reported revenue up 1.6% to $1.4 billion after a negative foreign exchange, ongoing headwinds from China and one fewer trading day compared to the prior year.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

MATX, SNN, ALEX, PCB and LTH have been added to the Zacks Rank #1 (Strong Buy) List on April 29, 2025.

Smith & Nephew is undergoing a turnaround under CEO Deepak Nath, focusing on margin expansion and growth through surgical robotics and regenerative technologies. Despite trading at a discount to peers, the company shows visible margin improvement, offering a compelling value proposition for investors. The base case projects 35% upside by 2025 with a 20% trading margin, while the bull case suggests 50-60% upside with further margin gains.

Global financial markets are in turmoil this morning after the US President announced sweeping tariffs on several countries in a push to lower the nation's trade deficit. Trump's new tariffs are particularly expected to hurt European companies with significant revenue exposure to the United States.

Shares in Smith & Nephew PLC (LSE:SN) fell 2% after UBS downgraded stock in the med-tech firm to 'neutral' from 'buy' on valuation grounds. The price target remains at £12.50.